Cargando…
Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas
Tumor Treating Fields (TTFields) were incorporated into the treatment of glioblastoma, the most malignant brain tumor, after showing an effect on progression-free and overall survival in a phase III clinical trial. The combination of TTFields and an antimitotic drug might further improve this approa...
Autores principales: | Krex, Dietmar, Bartmann, Paula, Lachmann, Doris, Hagstotz, Alexander, Jugel, Willi, Schneiderman, Rosa S., Gotlib, Karnit, Porat, Yaara, Robel, Katja, Temme, Achim, Giladi, Moshe, Michen, Susanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003311/ https://www.ncbi.nlm.nih.gov/pubmed/36902447 http://dx.doi.org/10.3390/ijms24055016 |
Ejemplares similares
-
Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors
por: Jugel, Willi, et al.
Publicado: (2021) -
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011) -
AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields)
por: Shteingauz, Anna, et al.
Publicado: (2018) -
Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
por: Dennis, Mike, et al.
Publicado: (2012) -
Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis
por: Schau, Isabell, et al.
Publicado: (2019)